Speech-Language Pathologists in Laguna, NM Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Mrs. Michelle Renee Bourguet-jio, MS,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: I-40 West Exit 114 Travel Rd 55, Laguna, NM 87026 Phone: 505-552-9091 |
 Anthony John Flores, ASL Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: I-40 West, Exit 114, Building #1125, Laguna, NM 87026 Phone: 505-552-6008 Fax: 505-552-6398 |
News Archive
Improved toxicology test method
Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.
Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company's lead immunotherapeutic.
Eliza to participate in a panel discussion at 2010 World Health Care Congress
Eliza Corporation, the leading provider of integrated healthcare communication strategies, will participate in a moderated discussion at the 2010 World Health Care Congress. The panel, entitled "Redesign for the New Consumer Customer," will explore the drivers that increase healthcare consumer satisfaction and address these consumer values to foster changes in health care design and delivery.
Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients
Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.
› Verified 9 days ago